In their 2022 paper, Abdi et al found the germline rates of 4.1%, 2% and 0.5% for BRCA2, ATM and BRCA1 in 557 patients with metastatic disease; these are similar to our rates of 5.7%, 1.9% and 0.3% in 322 cases. Here, BRCA2 is linked to metastatic neoplasm.